Authors
Ya Guo, Satoshi Saito, Kenji Makita, Tomohiro Enokida, Takashi Hiyama, Ryo Kuboki, Hirofumi Kuno, Masaki Nakamura, Yuichi Hiroshima, Hidenari Hirata, Masashi Wakabayashi, Yunhao Zhang, Nobukazu Tanaka, Makoto Tahara, Sadamoto Zenda
Published in
International journal of clinical oncology. Oct 09, 2026. Epub Oct 09, 2026.
Abstract
This study aimed to evaluate the association between total tumor volume reduction rate (VRR) and treatment outcomes in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) treated with paclitaxel, carboplatin, and cetuximab (PCE)-based induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT).
Patients with LA-NPC who were planned to undergo IC-PCE followed by CCRT between September 2017 and December 2024 were included. Overall survival (OS) and progression-free survival (PFS) were calculated, and factors associated with PFS were evaluated. VRR was dichotomized based on a cutoff value derived from receiver operating characteristic curve analysis.
In total, 43 consecutive patients with LA-NPC (median age, 56 years) were included. The median follow-up time was 48 months (Interquartile Range, 34-69). The 3-year OS and PFS were 95.3% and 76.1%, respectively. A total of 12 PFS events were observed, including locoregional recurrence (n = 3), distant metastasis (n = 6), both (n = 1), and death (n = 2). In multivariable analysis adjusted for cStage (Union for International Cancer Control 9th edition), a high VRR (cutoff value, 48.6%) was identified as a significant factor associated with improved PFS (hazard ratio, 0.21; 95% confidence interval, 0.06-0.70; p = 0.01).
VRR was associated with PFS, suggesting that tumor shrinkage following IC-PCE may serve as a prognostic marker.
PMID:
42853545
Bibliographic data and abstract were imported from PubMed on 10 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0